RU2008136193A - Детектирование рака по повышенным уровням bcl-2 - Google Patents
Детектирование рака по повышенным уровням bcl-2 Download PDFInfo
- Publication number
- RU2008136193A RU2008136193A RU2008136193/15A RU2008136193A RU2008136193A RU 2008136193 A RU2008136193 A RU 2008136193A RU 2008136193/15 A RU2008136193/15 A RU 2008136193/15A RU 2008136193 A RU2008136193 A RU 2008136193A RU 2008136193 A RU2008136193 A RU 2008136193A
- Authority
- RU
- Russia
- Prior art keywords
- bcl
- sample
- cancer
- subject
- binding agent
- Prior art date
Links
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 title claims abstract 19
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 title claims abstract 19
- 238000001514 detection method Methods 0.000 title claims abstract 10
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 9
- 201000011510 cancer Diseases 0.000 title claims abstract 9
- 238000000034 method Methods 0.000 claims abstract 15
- 239000000523 sample Substances 0.000 claims abstract 11
- 239000012472 biological sample Substances 0.000 claims abstract 8
- 210000002700 urine Anatomy 0.000 claims abstract 6
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 claims abstract 5
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 claims abstract 5
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract 2
- 239000011230 binding agent Substances 0.000 claims 10
- 239000013060 biological fluid Substances 0.000 claims 9
- 239000000107 tumor biomarker Substances 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 claims 1
- 239000003547 immunosorbent Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
1. Способ детектирования рака у субъекта, предусматривающий детектирование присутствия Bcl-2 в биологической пробе, полученной из организма указанного субъекта, где уровень Bcl-2 выше предопределенного порога служит признаком наличия рака у указанного субъекта. ! 2. Способ по п.1, где указанное детектирование предусматривает ! (a) приведение биологической пробы в контакт со связывающим агентом, который связывается с белком Bcl-2, с образованием комплекса; ! (b) детектирование указанного комплекса; и установление корреляции детектируемого комплекса с количеством белка Bcl-2 в пробе, причем наличие повышенного уровня белка Bcl-2 служит признаком наличия рака. ! 3. Способ по п.1, где биологической пробой является моча. ! 4. Способ по п.1, где рак представляет собой рак яичника. ! 5. Способ по п.2, где связывающий агент иммобилизован на носителе. ! 6. Способ по п.5, где при указанном детектировании (b) используют иммуноферментное детектирование на основе ELISA. ! 7. Способ по п.1, дополнительно предусматривающий детектирование биомаркера рака в одной и той же биологической пробе или в другой биологической пробе, полученной из организма указанного субъекта, до, в процессе или после указанного детектирования Bcl-2. ! 8. Способ по п.7, где биомаркером рака является CA125, LPA или OVXI. ! 9. Способ по п.1, где субъект не проявляет симптомов рака в момент проведения указанного детектирования. ! 10. Устройство для быстрого детектирования Bcl-2 в пробе биологической жидкости, содержащее зону нанесения для поступившей пробы биологической жидкости; зону мечения, содержащую связывающий агент, который связывается с Bcl-2 в пробе; и зону детектирования, где Bcl-2-связанный связыва
Claims (19)
1. Способ детектирования рака у субъекта, предусматривающий детектирование присутствия Bcl-2 в биологической пробе, полученной из организма указанного субъекта, где уровень Bcl-2 выше предопределенного порога служит признаком наличия рака у указанного субъекта.
2. Способ по п.1, где указанное детектирование предусматривает
(a) приведение биологической пробы в контакт со связывающим агентом, который связывается с белком Bcl-2, с образованием комплекса;
(b) детектирование указанного комплекса; и установление корреляции детектируемого комплекса с количеством белка Bcl-2 в пробе, причем наличие повышенного уровня белка Bcl-2 служит признаком наличия рака.
3. Способ по п.1, где биологической пробой является моча.
4. Способ по п.1, где рак представляет собой рак яичника.
5. Способ по п.2, где связывающий агент иммобилизован на носителе.
6. Способ по п.5, где при указанном детектировании (b) используют иммуноферментное детектирование на основе ELISA.
7. Способ по п.1, дополнительно предусматривающий детектирование биомаркера рака в одной и той же биологической пробе или в другой биологической пробе, полученной из организма указанного субъекта, до, в процессе или после указанного детектирования Bcl-2.
8. Способ по п.7, где биомаркером рака является CA125, LPA или OVXI.
9. Способ по п.1, где субъект не проявляет симптомов рака в момент проведения указанного детектирования.
10. Устройство для быстрого детектирования Bcl-2 в пробе биологической жидкости, содержащее зону нанесения для поступившей пробы биологической жидкости; зону мечения, содержащую связывающий агент, который связывается с Bcl-2 в пробе; и зону детектирования, где Bcl-2-связанный связывающий агент удерживается для подачи сигнала, причем сигнал, подаваемый в случае пробы, полученной из организма субъекта, с уровнем Bcl-2, более низким, чем пороговая концентрация, отличается от сигнала, подаваемого в случае пробы, полученной из организма пациента, с уровнем Bcl-2, более высоким, чем пороговая концентрация.
11. Устройство по п.10, где биологической жидкостью является моча, а указанная пороговая концентрация составляет от 0 до 2,0 нг/мл.
12. Устройство по п.11, где биологической жидкостью является моча, а указанная пороговая концентрация составляет 1,8 нг/мл.
13. Устройство по п.10, где указанное устройство имеет ссылочную зону, которая подает сигнал, который имеет ту же самую интенсивность, что и сигнал, подаваемый в зоне детектирования в случае пробы из организма субъекта, имеющего уровень Bcl-2, равный пороговой концентрации.
14. Устройство по п.10, где связывающий агент является меченым моноклональным антителом.
15. Способ измерения Bcl-2 в биологической жидкости, предусматривающий (а) получение пробы биологической жидкости из организма субъекта; (b) приведение указанной пробы в контакт со связывающим агентом, который связывается с любым Bcl-2 в пробе; (с) выделение Bcl-2-связанного связывающего агента; (d) детектирование сигнала, ассоциированного с выделенным связывающим агентом из (с); и (е) сравнение сигнала, детектируемого на стадии (d), со ссылочным сигналом, который соответствует сигналу, подаваемому пробой, полученной из организма субъекта, с уровнем Bcl-2, равным пороговой концентрации.
16. Способ по п.15, где биологической жидкостью является моча, а указанная пороговая концентрация составляет от 0 до 2,0 нг/мл.
17. Способ по п.15, где биологической жидкостью является моча, а указанная пороговая концентрация составляет 1,8 нг/мл.
18. Набор для детектирования рака в биологической пробе, содержащий связывающий агент, специфичный в отношении Bcl-2, и напечатанные инструкции для детектирования рака в биологической жидкости с использованием указанного связывающего агента.
19. Набор по п.18, дополнительно содержащий один или более протеиназных ингибиторов для применения к биологической пробе.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77167706P | 2006-02-09 | 2006-02-09 | |
| US60/771,677 | 2006-02-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008136193A true RU2008136193A (ru) | 2010-03-20 |
| RU2436098C2 RU2436098C2 (ru) | 2011-12-10 |
Family
ID=38345845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008136193/15A RU2436098C2 (ru) | 2006-02-09 | 2007-02-09 | Детектирование рака яичника по повышенным уровням bcl-2 в моче |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8034549B2 (ru) |
| EP (1) | EP1996940B1 (ru) |
| JP (1) | JP4896994B2 (ru) |
| KR (1) | KR20080114689A (ru) |
| CN (1) | CN101384903A (ru) |
| AT (1) | ATE538386T1 (ru) |
| AU (1) | AU2007212278A1 (ru) |
| BR (1) | BRPI0707645B8 (ru) |
| CA (1) | CA2642051C (ru) |
| IL (1) | IL192866A (ru) |
| NO (1) | NO20083820L (ru) |
| NZ (1) | NZ570008A (ru) |
| RU (1) | RU2436098C2 (ru) |
| SG (1) | SG169395A1 (ru) |
| WO (1) | WO2007092627A2 (ru) |
| ZA (1) | ZA200805787B (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10808283B2 (en) | 2013-08-19 | 2020-10-20 | Biontech Diagnostics Gmbh | Methods and kits for the molecular subtyping of tumors |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0307403D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Selection by compartmentalised screening |
| GB0307428D0 (en) * | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
| US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
| US20050221339A1 (en) * | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
| US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
| AU2006335290A1 (en) | 2006-01-11 | 2007-07-19 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
| NZ570008A (en) | 2006-02-09 | 2011-10-28 | Univ South Florida | Detection of ovarian cancer by elevated levels of Bcl-2 in urine |
| US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
| EP2021113A2 (en) | 2006-05-11 | 2009-02-11 | Raindance Technologies, Inc. | Microfluidic devices |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| AU2007253740A1 (en) * | 2006-05-18 | 2007-11-29 | Molecular Profiling Institute, Inc. | System and method for determining individualized medical intervention for a disease state |
| EP3536396B1 (en) | 2006-08-07 | 2022-03-30 | The President and Fellows of Harvard College | Fluorocarbon emulsion stabilizing surfactants |
| US8772046B2 (en) | 2007-02-06 | 2014-07-08 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
| US8592221B2 (en) * | 2007-04-19 | 2013-11-26 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
| WO2009055813A1 (en) * | 2007-10-25 | 2009-04-30 | The Research Foundation Of State University Of New York | Apparatus and method of detection and localized treatment of abnormal conditions |
| US12038438B2 (en) | 2008-07-18 | 2024-07-16 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
| WO2010009365A1 (en) | 2008-07-18 | 2010-01-21 | Raindance Technologies, Inc. | Droplet libraries |
| CA2999537C (en) * | 2008-10-10 | 2021-10-19 | Dana-Farber Cancer Institute | Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides |
| EP2411148B1 (en) | 2009-03-23 | 2018-02-21 | Raindance Technologies, Inc. | Manipulation of microfluidic droplets |
| US8328795B2 (en) * | 2009-04-03 | 2012-12-11 | Candela Corporation | Skin resurfacing at 1930 nm |
| EP2848700B1 (en) * | 2009-07-24 | 2017-10-04 | Geadic Biotec, AIE. | Markers for endometrial cancer |
| US10520500B2 (en) | 2009-10-09 | 2019-12-31 | Abdeslam El Harrak | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
| WO2011056688A2 (en) * | 2009-10-27 | 2011-05-12 | Caris Life Sciences, Inc. | Molecular profiling for personalized medicine |
| US10837883B2 (en) | 2009-12-23 | 2020-11-17 | Bio-Rad Laboratories, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
| EP3392349A1 (en) | 2010-02-12 | 2018-10-24 | Raindance Technologies, Inc. | Digital analyte analysis |
| US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
| US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
| US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
| US9562897B2 (en) | 2010-09-30 | 2017-02-07 | Raindance Technologies, Inc. | Sandwich assays in droplets |
| KR101931936B1 (ko) * | 2010-11-05 | 2018-12-26 | 에이자이 아이엔씨. | 엽산 수용체 알파-발현 암에 대한 진단 및 예후 마커로서의 엽산 수용체 알파 |
| US9364803B2 (en) | 2011-02-11 | 2016-06-14 | Raindance Technologies, Inc. | Methods for forming mixed droplets |
| US9150852B2 (en) | 2011-02-18 | 2015-10-06 | Raindance Technologies, Inc. | Compositions and methods for molecular labeling |
| AU2012222192A1 (en) * | 2011-02-23 | 2013-10-17 | Mdsure Ltd | Compositions and methods for personal tumor profiling treatment |
| US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
| US9556470B2 (en) | 2011-06-02 | 2017-01-31 | Raindance Technologies, Inc. | Enzyme quantification |
| US9334306B2 (en) | 2011-07-09 | 2016-05-10 | The Regents Of The University Of California | Leukemia stem cell targeting ligands and methods of use |
| US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
| WO2013035095A1 (en) * | 2011-09-08 | 2013-03-14 | Ben-Gurion University Of The Negev Research And Development Authority | Methods for diagnosing cancer |
| EP2758777B1 (en) * | 2011-09-22 | 2018-02-07 | Memorial Sloan-Kettering Cancer Center | Detecting ovarian cancer |
| US20130102003A1 (en) * | 2011-10-21 | 2013-04-25 | Decimadx, Llc | Point-of-Care Immunoassay for Quantitative Small Analyte Detection |
| WO2013120089A1 (en) | 2012-02-10 | 2013-08-15 | Raindance Technologies, Inc. | Molecular diagnostic screening assay |
| WO2013165748A1 (en) | 2012-04-30 | 2013-11-07 | Raindance Technologies, Inc | Digital analyte analysis |
| WO2014172288A2 (en) | 2013-04-19 | 2014-10-23 | Raindance Technologies, Inc. | Digital analyte analysis |
| US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
| US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
| EP3090063B1 (en) | 2013-12-31 | 2019-11-06 | Bio-Rad Laboratories, Inc. | Method for detection of latent retrovirus |
| EP3158085B1 (en) | 2014-06-18 | 2020-12-02 | Clear Gene, Inc. | Methods for rapid analysis of biological markers |
| CN114410830A (zh) | 2014-09-17 | 2022-04-29 | 豪洛捷公司 | 部分裂解和测定的方法 |
| GB201417281D0 (en) * | 2014-09-30 | 2014-11-12 | Ge Healthcare Uk Ltd | Methods and devices relating to the detection of oral cancer biomarkers |
| JP5995117B2 (ja) * | 2015-01-26 | 2016-09-21 | 国立大学法人 筑波大学 | 可溶型ｃｄ１５５タンパク質を用いた癌の検出方法 |
| US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
| AU2016369603A1 (en) | 2015-12-18 | 2018-07-05 | Clear Gene, Inc. | Methods, compositions, kits and devices for rapid analysis of biological markers |
| US12275994B2 (en) | 2017-06-22 | 2025-04-15 | Clear Gene, Inc. | Methods and compositions for the analysis of cancer biomarkers |
| US10998178B2 (en) | 2017-08-28 | 2021-05-04 | Purdue Research Foundation | Systems and methods for sample analysis using swabs |
| EP3817756A4 (en) * | 2018-07-05 | 2022-03-30 | Ovation Diagnostics LLC | ANTI-BCL-2 ANTIBODIES AND IMMUNOLOGICAL ASSAY FOR THE DIAGNOSIS OF CANCER |
| CN109374897B (zh) * | 2018-11-22 | 2021-11-02 | 大连大学 | 一种用于肝癌检测的试剂盒 |
| CN114761809B (zh) * | 2019-12-06 | 2025-02-25 | 普罗体哪有限公司 | 预测bcl2家族蛋白靶向药物的反应性的方法 |
| WO2021216691A1 (en) * | 2020-04-21 | 2021-10-28 | Croce Carlo M | Methods of detecting and treating cancers characterized by loss of mir15 and mir16 expression |
| WO2021231296A1 (en) * | 2020-05-12 | 2021-11-18 | Lonza Houston, Inc. | Methods and kits for detecting adeno-associated viruses |
| CN111679076A (zh) * | 2020-06-15 | 2020-09-18 | 吉林医药学院 | 一种用于检测cyclinD1和BCL-2抗体的检测试剂盒 |
| EP4511513A1 (en) * | 2022-06-01 | 2025-02-26 | Northeastern University | Enhanced specificity mass tag dna adductomics |
| WO2025075824A1 (en) * | 2023-10-02 | 2025-04-10 | Siemens Healthcare Diagnostics Inc. | Urine sediment interface with probabilistic classification binning and methods of producing and using same |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3654090A (en) | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4381291A (en) | 1979-02-23 | 1983-04-26 | Ab Fortia | Measurement of free ligands |
| US4260678A (en) | 1979-02-23 | 1981-04-07 | Corning Glass Works | Determining creatine kinase isoenzmes via immobilized antibody-isoenzyme complexes |
| US4343312A (en) | 1979-04-16 | 1982-08-10 | Vitafin N.V. | Pacemaker output circuit |
| FR2455743A1 (fr) | 1979-05-02 | 1980-11-28 | Goella Laboratoires | Procede et dispositif pour le dosage des lipoproteines seriques |
| US4357311A (en) | 1980-10-03 | 1982-11-02 | Warner-Lambert Company | Substrate for immunoassay and means of preparing same |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| JPS59500735A (ja) | 1983-04-18 | 1984-04-26 | エス・ア−ル・アイ・インタ−ナシヨナル | 人間の癌診断のための方法および試験キツト |
| US4617261A (en) | 1984-03-21 | 1986-10-14 | Cetus Corporation | Process for labeling nucleic acids and hybridization probes |
| US4582789A (en) | 1984-03-21 | 1986-04-15 | Cetus Corporation | Process for labeling nucleic acids using psoralen derivatives |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5015568A (en) * | 1986-07-09 | 1991-05-14 | The Wistar Institute | Diagnostic methods for detecting lymphomas in humans |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5356817A (en) | 1988-06-09 | 1994-10-18 | Yale University | Methods for detecting the onset, progression and regression of gynecologic cancers |
| US5312922A (en) | 1992-04-06 | 1994-05-17 | Nordion International Inc. | Europium and terbium chelators for time-resolved fluorometric assays |
| EP0689673B1 (en) * | 1993-03-17 | 1997-07-02 | Akzo Nobel N.V. | Apparatus for the detection of a specifically reacting substance |
| US5539094A (en) * | 1993-11-12 | 1996-07-23 | La Jolla Cancer Research Foundation | DNA encoding Bcl-2-associated proteins |
| US5695944A (en) * | 1995-05-05 | 1997-12-09 | Thomas Jefferson University | Modulation of bcl-2 phosphorylation |
| US6811995B1 (en) | 1996-04-26 | 2004-11-02 | Children's Medical Center Corporation | Non-invasive enzyme screen for cancer |
| US5821082A (en) * | 1996-05-23 | 1998-10-13 | St. Louis University Health Sciences Center | Anti-proliferation domain of a human Bcl-2 and DNA encoding the same |
| DE19936618A1 (de) * | 1999-08-04 | 2001-03-15 | Monotec Gmbh | Diagnostisches Kit und dessen Verwendung |
| WO2001057060A1 (en) * | 2000-02-01 | 2001-08-09 | Human Genome Sciences, Inc. | Bcl-2-like polynucleotides, polypeptides, and antibodies |
| KR100414637B1 (ko) * | 2000-02-08 | 2004-01-13 | (주)에스제이바이오메드 | 사람 미토콘드리아 아데닐레이트 키나제 이소자임들에대한 항체와 면역학적 제제 및 심장질환 진단키트 |
| AU2001253140A1 (en) | 2000-04-03 | 2001-10-15 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Tumor markers in ovarian cancer |
| US6492127B2 (en) * | 2001-01-23 | 2002-12-10 | Varian, Inc. | Lateral flow testing device with on-board chemical reactant |
| WO2002090931A2 (en) | 2001-05-07 | 2002-11-14 | The Burnham Institute | Methods for determining the prognosis for cancer patients using tucan |
| JP4256169B2 (ja) * | 2001-05-07 | 2009-04-22 | ザ バーナム インスティチュート | Ｔｕｃａｎを用いて癌患者の予後を決定するための方法 |
| WO2003078662A1 (en) | 2002-03-13 | 2003-09-25 | Genomic Health | Gene expression profiling in biopsied tumor tissues |
| KR20030092378A (ko) | 2002-05-29 | 2003-12-06 | 박영미 | 고형암의 진행 정도를 진단하는 방법 및 키트 |
| WO2003105899A1 (en) * | 2002-06-13 | 2003-12-24 | Neuropro Technologies, Inc. | Apparatus and methods for detecting cerebrospinal fluid |
| CN1402004A (zh) * | 2002-09-27 | 2003-03-12 | 江西中德生物工程有限公司 | 一种免疫层析一步法检测β－肾上腺素激动剂类药物的方法及试纸的制备 |
| US20040137538A1 (en) * | 2003-01-10 | 2004-07-15 | Bradford Sherry A. | Cancer comprehensive assay kit for identifying cancer protein patterns |
| US7288383B2 (en) | 2003-01-15 | 2007-10-30 | The Brigham And Women's Hospital, Inc. | Eosinophil-derived neurotoxin as a marker for ovarian cancer |
| EP1802974B1 (en) * | 2004-09-30 | 2009-01-07 | Quidel Corporation | Analytical devices with primary and secondary flow paths |
| NZ570008A (en) | 2006-02-09 | 2011-10-28 | Univ South Florida | Detection of ovarian cancer by elevated levels of Bcl-2 in urine |
-
2007
- 2007-02-09 NZ NZ570008A patent/NZ570008A/en unknown
- 2007-02-09 US US11/704,408 patent/US8034549B2/en active Active
- 2007-02-09 WO PCT/US2007/003608 patent/WO2007092627A2/en not_active Ceased
- 2007-02-09 SG SG201100891-9A patent/SG169395A1/en unknown
- 2007-02-09 BR BRPI0707645A patent/BRPI0707645B8/pt active IP Right Grant
- 2007-02-09 AU AU2007212278A patent/AU2007212278A1/en not_active Abandoned
- 2007-02-09 KR KR1020087019574A patent/KR20080114689A/ko not_active Withdrawn
- 2007-02-09 CA CA2642051A patent/CA2642051C/en active Active
- 2007-02-09 JP JP2008554404A patent/JP4896994B2/ja not_active Expired - Fee Related
- 2007-02-09 AT AT07763533T patent/ATE538386T1/de active
- 2007-02-09 EP EP07763533A patent/EP1996940B1/en active Active
- 2007-02-09 RU RU2008136193/15A patent/RU2436098C2/ru not_active IP Right Cessation
- 2007-02-09 CN CNA2007800049603A patent/CN101384903A/zh active Pending
-
2008
- 2008-07-02 ZA ZA200805787A patent/ZA200805787B/xx unknown
- 2008-07-17 IL IL192866A patent/IL192866A/en not_active IP Right Cessation
- 2008-09-08 NO NO20083820A patent/NO20083820L/no not_active Application Discontinuation
-
2011
- 2011-08-08 US US13/205,095 patent/US20110318763A1/en not_active Abandoned
-
2016
- 2016-05-20 US US15/160,649 patent/US20160258960A1/en not_active Abandoned
-
2018
- 2018-11-14 US US16/190,475 patent/US11156613B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10808283B2 (en) | 2013-08-19 | 2020-10-20 | Biontech Diagnostics Gmbh | Methods and kits for the molecular subtyping of tumors |
Also Published As
| Publication number | Publication date |
|---|---|
| US20080009005A1 (en) | 2008-01-10 |
| EP1996940A4 (en) | 2009-10-21 |
| NZ570008A (en) | 2011-10-28 |
| CA2642051C (en) | 2017-01-24 |
| US11156613B2 (en) | 2021-10-26 |
| SG169395A1 (en) | 2011-03-30 |
| US8034549B2 (en) | 2011-10-11 |
| AU2007212278A1 (en) | 2007-08-16 |
| ATE538386T1 (de) | 2012-01-15 |
| BRPI0707645B1 (pt) | 2019-04-09 |
| EP1996940B1 (en) | 2011-12-21 |
| BRPI0707645B8 (pt) | 2021-07-27 |
| IL192866A (en) | 2013-04-30 |
| WO2007092627A9 (en) | 2007-10-18 |
| US20160258960A1 (en) | 2016-09-08 |
| WO2007092627A2 (en) | 2007-08-16 |
| JP4896994B2 (ja) | 2012-03-14 |
| CN101384903A (zh) | 2009-03-11 |
| ZA200805787B (en) | 2009-05-27 |
| CA2642051A1 (en) | 2007-08-16 |
| EP1996940A2 (en) | 2008-12-03 |
| US20190072556A1 (en) | 2019-03-07 |
| KR20080114689A (ko) | 2008-12-31 |
| US20110318763A1 (en) | 2011-12-29 |
| BRPI0707645A2 (pt) | 2011-05-10 |
| WO2007092627A3 (en) | 2008-11-13 |
| JP2009526234A (ja) | 2009-07-16 |
| RU2436098C2 (ru) | 2011-12-10 |
| NO20083820L (no) | 2008-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008136193A (ru) | Детектирование рака по повышенным уровням bcl-2 | |
| Eletxigerra et al. | Surface plasmon resonance immunosensor for ErbB2 breast cancer biomarker determination in human serum and raw cancer cell lysates | |
| MX2007014815A (es) | Metodos de inmunoanalisis mejorados. | |
| JP7102406B2 (ja) | エキソソームの亜集団の定量および神経変性障害の診断 | |
| EP3253800B1 (en) | Prostate antigen standards and uses thereof | |
| ATE539816T1 (de) | Verfahren zum diagnostischen testen | |
| ATE267399T1 (de) | Verfahren zum nachweis von komplex-gebundenem prostata-spezifischem antigen (kpsa) | |
| RU2011125320A (ru) | Способы, устройства и наборы для детекции или мониторинга острого повреждения почек | |
| RU2011140471A (ru) | Способ диагностики эндометриоза и диагностический набор для эндометриоза | |
| US20180180617A1 (en) | Intergrin alpha v beta 6 for diagnosis/prognosis of colorectal carcinoma | |
| DE602005009819D1 (de) | Verfahren zum nachweis von infektionen mit mykobakterien | |
| Gholami et al. | A paper-based optical sensor for the screening of viruses through the cysteine residues of their surface proteins: A proof of concept on the detection of coronavirus infection | |
| SI24638A (sl) | Fluorometrična imunska metoda za določanje protiteles proti dvojnoverižni DNA | |
| JP2015503921A (ja) | 結腸直腸癌診断および予測のためのバイオマーカー | |
| KR101815253B1 (ko) | 간 섬유화 진단용 바이오마커 cxcl14 | |
| WO2006123789A1 (ja) | 酵素分析方法 | |
| RU2008130888A (ru) | Мас-2вр как маркер для диагностики рака желудка | |
| KR20170010526A (ko) | 암 진단용 elisa 키트 및 그를 이용한 암 진단 방법 | |
| CN105929151A (zh) | 前列腺特异性抗原同源异构体化学发光免疫检测试剂盒及其制备方法 | |
| CN106153923B (zh) | 预测谷丙转氨酶小于二倍正常上限的慢性乙型病毒性肝炎患者肝脏炎症程度的系统 | |
| Maksym et al. | Determination of the concentration of polyamines with SPR-based immune biosensor for early diagnostics of breast cancer | |
| CN102213724A (zh) | 一种基于化学发光的痕量蛋白快速检测方法 | |
| Maeda et al. | Urinary carboxylesterase 5A fragment as an early diagnostic marker of cat chronic kidney disease | |
| WO2006060188A3 (en) | Anti-tenascin monoclonal antibody immunoassays and diagnostic kits | |
| KR20200045131A (ko) | 장형 위암의 예후 진단 마커 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20130210 |